Credible Market Trends Augmenting the Growth of the Global Anti-Malaria Drugs Market
Many countries of the world are prone to the risk of malaria transmission which has driven large number of partners and resources to rapidly increase malaria control efforts and efficient management strategies such as prevention control, resources for early diagnosis and efficient anti-malaria drugs to minimize the effects. The worldwide demand for anti-malaria drugs is increasing on the back of massive growth of healthcare industry across the globe. Further, increasing awareness about early symptoms, constant monitoring and easy availability of therapeutics is predicted to benefit the expansion of the global anti-malaria drugs market with a CAGR of 3.2% over the forecast period i.e. 2018-2027. The global anti-malaria drugs market accounted for USD 742.5 Million in 2016 and is predicted to reach USD 1,049.5 Million in 2027. The market is expected to grow with a Y-O-Y growth rate of 3.4% in the year 2027.
Growth Highlights based upon Regional Platform during 2016-2027
The global anti-malaria drugs market is segmented by regions into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa, out of which, Middle East & Africa anti-malaria drugs market accounted for more than 50% of the market share during 2016 which can be attributed to growing rate of malaria cases and lack of resources to control the local transmission of the disease in this region. Further, the Middle East & Africa is believed to dominate the overall anti-malaria drugs market during the forecast period.
The second largest share of 30% was held by the Asia Pacific anti-malaria drugs market which is anticipated to cross USD 300 Million by 2027. China & India are the major contributors behind the growth of the Asia Pacific anti-malaria drugs market.CLICK TO DOWNLOAD FREE SAMPLE
Market Segmentation Synopsis
By Anti-malaria Activity
Global anti-malaria drugs market is segmented on the basis of anti-malaria activity into tissue schizonticides, blood schizonticides, gametocytocides, sporontocides & others. Among these segments, gametocytocides segment with 60.3% share in 2016, occupied the largest market of anti-malaria drugs across the globe. These drugs destroy the sexual forms of the parasite in the blood and thereby prevent transmission of the infection to the mosquito which is predicted to be the driving factor behind the positive growth of gametocytocides segment throughout the forecast period. Additionally, blood schizonticides segment held the second largest share of anti-malaria drugs market and is expected to achieve Y-o-Y growth rate of 3.4% in 2027.
By Drug Chemistry
The global anti-malaria drugs market is divided by drug chemistry into aryl amino alcohols, 4-aminoquinolines, folate synthesis inhibitors, 8-aminoquinolines, antimicrobials, peroxides, napthoquinones, iron chelating agents and others. Among these segments, the 4-aminoquinolines segment is estimated to capture the highest market share during the forecast period. This segment contributed around 26% market share of the total anti-malaria drugs market in 2016 and is projected to achieve Y-o-Y growth rate of 3.7% in 2027 as compared to previous year. Further, the 8-aminoquinolines and napthoquinones segment are estimated to grow significantly over the forecast period.
By Distribution Channel
The global market of anti-malaria drugs market is segmented by distribution channel into hospital pharmacy, retail pharmacy and others, out of which, the retail pharmacy segment contributed around 60% market share of the total anti-malaria drugs market in 2016 and is estimated to remain highest during the forecast period by expanding at a highest CAGR of 3.4% during the period 2018-2027. Further, hospital pharmacy segment is projected to achieve Y-o-Y growth rate of 3.3% in 2027.
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Market Drivers & Challenges
The global anti-malaria drugs market is thriving on the back of growing rate of malaria effected fatalities around the globe. According to World Health Organization, in 2016, nearly half of the world's population was at risk of malaria. Also, most malaria cases and deaths occur in sub-Saharan Africa. In 2016, 91 countries and areas had ongoing malaria transmission as reported by W.H.O. The increasing prevalence of malaria due to changing environmental conditions, as well as increasing poverty in certain parts of the world is predicted to increase the demand for anti-malaria drugs over the forecast period.
Further, a number of promising anti-malaria drug discovery projects are being funded by the Medicines for Malaria Venture (MMV), a non-profit organization focused on anti-malaria drug discovery which is anticipated to lure giant market players into the research and developmental activity for anti-malaria drugs market. The growing demand for outcome based, preventive healthcare is estimate to increase the demand for anti-malaria drugs over the forecast period and is believed to aid the anti-malaria drugs market to expand during the forecast period.
There are possible side effects of the anti-malaria drugs such as insomnia, vivid dreams, mental clouding, dizziness, and anxiety. Such side effects associated with the anti-malaria drugs are anticipated in slower adoption rate of these drugs and thus, serve as a hindrance in the growth of the anti-malaria drugs market around the globe.
Some of the affluent industry leaders in the global anti-malaria drugs market are Mylan Labs, Cipla Ltd., GlaxoSmithKline Plc., Novartis AG, Roche Inc., Bayer AG, Lincoln Pharmaceuticals Ltd., Strides Pharma Science Limited, Glenmark Pharmaceutical and Alliance Pharmaceuticals Limited.
Novartis announced a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads. The R&D investment is meant to advance the Novartis malaria pipeline through 2023 and to complete a comprehensive global clinical trial program for its novel antimalarial drug candidates KAF156 and KAE609.
Moreover, other key and niche players are working towards the expansion of product portfolio along with investing in high quality R&D to expand their distribution channel in order to gain competitive edge in the global anti-malaria drugs market.
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization